Cross-office Corporate Team Demonstrates Life Sciences Capabilities for Emerging San Diego Companies
Mintz served as legal counsel to DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a biotechnology company focused on precision dermatology, in its $65 million private investment in public equity (PIPE) financing. The definitive securities purchase agreement closed on March 4.
Headquartered in La Jolla, California, DermTech is an innovator in genetic testing for skin cancers and other skin-related diseases, providing genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. The company markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.
In addition to providing working capital, the transaction will help support DermTech’s commercialization of its pigmented lesion assay, the first non-invasive gene expression test for the early detection of melanoma, and to accelerate pipeline development.
The Mintz team advising DermTech was led by Member and Co-chair of the Venture Capital & Emerging Companies Practice Jeremy Glaser, and included Associates Peter Cunningham, Jason Miller, and Christian Hollweg. In 2019, Mintz also represented DermTech in connection with its reverse merger with a publicly-traded special purpose acquisition company (SPAC).
Mintz is one of the leading law firms to the life sciences industry. The firm’s attorneys advise hundreds of businesses and other organizations across the sector—from start-ups and emerging growth companies to large public companies, as well as venture capital firms, investment banks, and research and academic institutions—on pivotal deals, mission-critical disputes, intellectual property, and regulatory matters.
Learn more about Mintz’s Life Sciences Practice here.
Learn more about the firm's Venture Capital & Emerging Companies Practice here.